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E6 oncoproteins from HPV-16 and bovine papillomavirus type 1 (BPV-1) bind to similar leucine-rich peptides termed
charged leucine motifs found on the cellular focal adhesion protein paxillin and the E3 ubiquitin ligase E6AP. BPV-1 E6 (BE6)
mutants that do not bind to paxillin are defective at inducing cellular transformation. It is possible, however, that BE6 mutants
that do not bind paxillin are defective for transformation for an unrelated reason than the ability to bind to charged leucine
motifs. To address the role of BE6 interaction with charged leucine motifs, we fused a BE6-binding charged leucine motif to
the amino terminus of BE6, thereby creating an autoinhibitory binding domain. We found that the fusion protein failed to bind
to paxillin or transform murine C127 cells. Mutation of the amino terminal binding motif in the fusion protein restored both
interaction with paxillin and transformation. This demonstrates that BE6 transformation requires binding to charged leucine
motifs on particular cellular proteins and that transformation by papillomavirus oncoproteins can be repressed by compet-












Papillomaviruses are causative agents for a variety of
benign and malignant epithelial neoplasms. Transforma-
tion by papillomaviruses is induced by the expression of
virus-encoded oncogenes E5, E6, and E7.
The E6 oncogenes are small zinc-binding proteins
with a conserved structure but surprisingly diverse ac-
tivities. The human papillomavirus (HPV) E6 oncopro-
teins that are associated with the development of ano-
genital cancers have been shown to alter the metabo-
lism of the p53 tumor suppressor. However, not all E6
oncoproteins target the degradation of p53 as neither the
bovine papillomavirus type 1 E6 (BE6) protein nor E6
proteins from HPV types 6 or 11 have shown the same
ability to target p53 for degradation (Scheffner et al.,
1990; Werness et al., 1990).
The E6 proteins of HPV-16 (16E6) and BE6 bind to the
cellular targets E6AP, ERC-55, and paxillin through inter-
action with homologous peptide sequences found on the
target proteins (Chen et al., 1998; Elston et al., 1998;
Vande Pol et al., 1998). The BE6 interaction motif found
within E6AP and paxillin contains the consensus LXX-
LL(A/G)X, where some of the X positions are glutamic or
aspartic acid. The BE6-interacting peptide sequence is
similar to previously described peptide binding motifs
termed in different laboratories “charged leucine motifs”
(Torchia et al., 1997) or “signature motifs” (Heery et al.,1 To whom reprint requests should be addressed. Fax: (216) 368-
300; E-mail: sbv@pop.cwru.edu.
1631997). These motifs, referred to here as charged leucine
motifs, have the consensus sequence of LXXLL and
mediate the interaction of transcription factors with tran-
scription factor coactivators. If the charged leucine mo-
tifs adopt an a-helical conformation, it is an amphipathic
elix with the leucines aligned upon one side of the helix.
harged leucine motifs on transcription factor coactiva-
ors bind to steroid hormone receptors in the presence of
igand, and the interaction is necessary for hormone-
nduced transcriptional activation by steroid receptors. It
s possible that charged leucine motifs serve to mediate
rotein interactions in extranuclear cellular compart-
ents. Paxillin is a BE6-interacting protein with five cop-
es of charged leucine binding motifs that are contained
ithin larger protein interaction motifs termed LD motifs
Brown et al., 1996). While the charged leucine motif has
the consensus LXXLL, paxillin LD motifs have the larger
consensus sequence (E/D)(V/L)DX(M/L)(M/L)X(D/E)L
(Brown et al., 1996). So while most LD motifs contain CL
motifs, the converse is not true.
It is clear that BE6 can bind to some proteins that
contain charged leucine motifs, but neither the specificity
nor role of this interaction in transformation by BE6 has
been fully defined. In particular, it is not clear if BE6 must
bind to particular protein targets that contain charged
leucine motifs or if binding of BE6 to charged leucine
motifs generically alters the structure of BE6 to allow for
transformation functions by BE6. In the latter case, bind-
ing by BE6 to charged leucine motifs on a variety of
proteins might be permissive for transformation, while in
the former case, only BE6 binding to charged leucine
motifs on specific cellular targets would result in trans-
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164 BOHL ET AL.formation. We have previously described BE6 mutants
that fail to bind to paxillin or E6AP and are defective for
transformation (Vande Pol et al., 1998). However, since
the BE6 molecule is altered by mutation in these exper-
iments, this does not eliminate either model as the mu-
tated BE6 might be altered to destroy transformation
function independent of interaction with a charged
leucine motif.
In this study we investigate if competitive binding for
charged leucine motifs could block transformation by a
papillomavirus E6 oncogene. If interaction with charged
leucine motifs alters the structure of BE6 for transforma-
tion, then small molecules devised to compete the inter-
action of BE6 with charged leucine motifs on cellular
proteins might not repress transformation by BE6. If,
however, BE6 must bind to charged leucine motifs on
specific target proteins, then competitive binding to al-
ternative binding motifs might repress cellular transfor-
mation by BE6.
RESULTS
We decided to first define a charged leucine motif of
paxillin that interacts with BE6 and then determine
whether coexpression of that motif together with BE6
could repress transformation by BE6. In paxillin, the CL
motifs are larger than a minimal charged leucine motif
and are termed LD motifs (Brown et al.,1998). While the
CL motif has the consensus LXXLL, LD motifs are larger
than CL motifs and have the consensus (L,V)(D,E)X(L,M)
(L,M)X(D,E)L (Brown et al.,1998). It is important to note
that the CL motifs found on the BE6 binding proteins
E6AP and E6BP are not LD motifs as they lack the
terminal leucine residue found in LD motifs. It was pre-
viously determined that BE6 principally binds to a paxillin
LD motif in the first 15 amino acids of paxillin (Tong et al.,
1997; Vande Pol et al., 1998). It has not yet been clear if
E6 interacts with the entire LD motif or just a portion of
t. The paxillin LD motif was expressed in vitro in rabbit
eticulocyte lysate as a fusion to glutathione–S trans-
erase and tested for in vitro association to an immobi-
ized MBP fusion to BE6. Amino acids 2–12 of the paxillin
ortion of the fusion were individually mutated as illus-
rated in Fig. 1. Alanine scanning mutagenesis defined
he paxillin-BE6 binding motif as DLDALLAD. Interaction
f BE6 with the first three leucines was specific with only
single hydrophobic amino acid substitution tolerated
mong the three leucines (L8F). Interaction with aspartic
cid was also specific as glutamic acid substitutions
ecreased binding (mutants D3E and D5E). However, it
s clear that motifs that diverge significantly from the
onserved paxillin LD motif can bind at levels near to that
f the LD motif as demonstrated by the L8F or L11K
utant paxillin motifs.
We reasoned that coexpression of a BE6 binding motif
ogether with BE6 might result in diminished transforma-ion efficiency by BE6. But we were unable to repress
E6 transformation by coexpression of LD motifs fused
o carrier proteins (unpublished observations).
To determine whether a charged leucine motif that is
oorly conserved with the paxillin LD motif could block
nteraction of BE6 with paxillin, we created BE6 fusion
roteins where a charged leucine binding motif was
used to the amino terminus of BE6 as illustrated in Fig.
. CL-BE6 (for “charged leucine-BE6”) contains amino
cids 1–11 of the paxillin LD motif with a L11K substitu-
ion. This mutant LD peptide binds to BE6 similarly to the
ild-type paxillin motif (Fig. 1), yet the L11K mutation is
ighly divergent from the conserved LD motif found in
axillin molecules and is therefore unlikely to share the
ame function as the wild-type LD motif of paxillin when
xpressed in cells. This was done to avoid possible
rtifacts that might result from the expression of intact
D motifs within cells. Four additional different peptide
usions to the amino terminus of BE6 were constructed
here the charged leucine motif was mutated in a way
redicted to reduce the affinity of the fused peptide for
E6 based upon the binding data shown in Fig. 1. Figure
illustrates the fusion proteins. CL(L4I/L8I)-BE6 contains
wo leucine to isoleucine substitutions within the
harged leucine motif that destroy the ability of the
harged leucine motif to interact with BE6 (Fig. 2). This
utant serves as a control for possible alteration in
ransformation by BE6 as a consequence of any fusion of
equence to the amino terminus.
To determine whether the CL motif fused to the amino
erminus of BE6 could block interaction of the fusion with
axillin, we tested the ability of BE6, EEPV-E6 (European
lk papillomavirus E6, an E6 type that does not interact
ith paxillin), CL-BE6, and CL(L4I/L8I)-BE6 to bind to
mmobilized paxillin in vitro. While in vitro translated BE6
and CL(L4I/L8I)-BE6 bound to immobilized paxillin, CL-
BE6 showed no detectable interaction with paxillin in
vitro (Fig. 3A). We also tested the interaction of GST
fusions of BE6, CL-BE6, and CL(L4I/L8I)-BE6 to interact
with paxillin in vitro in bacterial lysates in the absence of
mammalian proteins and found that while BE6 and
CL(L4I/L8I)-BE6 interacted with paxillin in vitro, CL-BE6
did not interact with paxillin (Fig. 3B). Since CL(L4I/L8I)-
BE6 differs from CL-BE6 only in the charged leucine motif
and not within the BE6 sequences, this is most consis-
tent with the CL motif acting as an inhibitory BE6 binding
domain in CL-BE6.
We next determined the comparative ability of BE6,
CL-BE6, and CL-BE6 with various mutations in the
charged leucine motif to induce morphological transfor-
mation and anchorage-independent cell growth. BE6,
CL-BE6, and CL-mutated BE6 genes packaged as retro-
viruses were used to infect C127 cells. Murine C127 cells
are contact inhibited and fail to proliferate when sus-
pended in agar. C127 cells transduced with either empty
retroviral vector or CL-BE6 were contact inhibited and
c
ed in th
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165REPRESSION OF E6 TRANSFORMATIONhad a similar morphology. C127 cells transduced with
FIG. 1. Interaction of mutant charged leucine motifs with BE6. Concep
and ERC-55 [I37371, (Chen et al., 1998)] are shown at the top with tra
hicken paxillin (L30099), murine HIC-5 (AA530718), and leupaxin (AF06
or mutants of paxillin and in vitro binding to a MBP-BE6 fusion is describ
as 30.8, 35, and 27% in three separate experiments. The percent bindin
D sequence normalized to 100% and is the average value of three seBE6 grew to higher cell density than C127 cells or CL-
BE6-transduced C127 cells (Fig. 4A). Mutations in the CLmotif predicted to ablate the interaction of the fused
nslations of the known BE6 binding motifs of E6AP (GenBank L07557)
ns of the amino-terminal 15 amino acids of human paxillin (U14588),
In vitro translations of GST fused to the first 15 amino acids of paxillin
e methods. The percent binding of input wild-type GST-LD to MBP-BE6
tant GST-LD motifs is expressed relative to the binding of the wild-type
experiments.tual tra
nslatio
2075).peptide with BE6 (CL(L4I/L8I)-BE6) grew to significantly












166 BOHL ET AL.while cells transduced with BE6 fused to CL peptides
that bound less well to BE6 in Fig. 1 grew to intermediate
cell densities in between that of CL-BE6 and CL(L4I/L8I)-
BE6. (Fig. 4A).
The same cell lines were tested for anchorage inde-
pendent cell growth (Fig. 4B and Table 1). C127 cells
transduced with empty retroviral vector failed to prolifer-
ate in agar, while C127 cells transduced with either
wild-type BE6 or CL(L4I/L8I)-BE6 were similar in their
ability to form colonies in agar. Although not apparent in
Fig. 4, rare anchorage-independent colonies were ob-
served in C127 cells transduced with CL-BE6 that were
not observed in C127 cells transduced with the empty
retrovirus. Thus the charged leucine motif on CL-BE6
reduced transformation efficiency compared to CL(L4I/
L8I)-BE6 by 20- to 400-fold (Table 1). BE6 fusions to CL
peptides with reduced binding to BE6 compared to the
peptide in CL-BE6 gave rise to anchorage-independent
colonies at higher frequencies. The order of mutants in
transformation efficiency in Fig. 4B is the reverse of the
order of the peptides in binding to BE6 from Fig. 1. In
other words, peptides with predicted greater binding to
BE6 caused greater repression of transformation when
fused to BE6.
It is possible that the CL-BE6 fusion molecule failed to
transform C127 cells due to reduced expression levels of
CL-BE6 compared to the CL(L4I/L8I)-BE6 fusion protein.
Expression levels of BE6, CL-BE6, and CL(L4I/L8I)-BE6 in
FIG. 2. BE6 fusions to charged leucine and mutant charged leucine m
the two zinc fingers of BE6. Below is the amino terminal sequence of B
CL-BE6 (for charged leucine-BE6). The fused CL sequence in CL-BE6 is
that binds BE6 well but is not conserved with the prototype LD motif. A
are shown and named for the mutation as indicated.the same stably expressing cell lines analyzed in Fig. 4
were examined by Western blot using antibody to BE6
t
t(Fig. 5). Both CL-BE6 and CL(L4I/L8I)-BE6 expression
were reduced in comparison to the wild-type BE6. But
the failure of CL-BE6 to efficiently transform C127 cells is
not due to reduced stability of CL-BE6 as CL-BE6 is
expressed at higher levels than the transformation pos-
itive CL(L4I/L8I)-BE6.
DISCUSSION
BE6 interacts with a portion of the LD motif of paxillin
(DLDALLAD) but does not interact with the full conserved
LD sequence DLDALLADL as BE6 does not require in-
teraction with the terminal leucine that is found in all the
LD motifs of paxillin, HIC-5, and leupaxin (Brown et al.,
1998). It is more accurate to say that BE6 interacts with
a CL motif contained within paxillin LD motifs. The size of
the paxillin binding motif in this study agrees with the
size of the motif in E6BP that interacts with BE6 (Chen et
l., 1998). The interaction of BE6 with its binding motif
ore resembles the interaction of transcription factors
ith transcription factor coactivators, where these inter-
cting motifs are termed signature motifs or charged
eucine motifs (Heery et al., 1997; Torchia et al., 1997). In
his regard, it is interesting that BE6 can act as a tran-
cription activation domain when fused to a DNA binding
omain, although transcriptional activation by BE6 may
e dispensable for transformation of established cell
ines (Lamberti et al., 1990; Ned et al., 1997). It is possible
hypothetical structural diagram of BE6 is shown at the top illustrating
e first zinc binding motif (CLWC) and the sequence of the BE6 mutant,
e sequence as the paxillin LD motif mutant L11K of Fig. 1, a LD mutant
lycine linker separates the CL motif from BE6. Mutants of the CL motifotifs. A
E6 to th
the samhat the ability of BE6 to activate transcription is related













































167REPRESSION OF E6 TRANSFORMATIONan as yet unidentified transcription factor. In this context,
it is noteworthy that BE6 is localized in stably trans-
formed cells to both nuclear and cytoplasmic compart-
FIG. 3. A charged leucine motif blocks interaction of BE6 with paxillin
n vitro. (A) BE6 and mutant BE6 fusion proteins were 35S-labeled and
xpressed in vitro in rabbit reticulocyte lysate. 10 ml of translated
roteins in reticulocyte lysate were mixed with 1 mg of MBP-paxillin
immobilized on agarose beads in 250 ml of N-P40 lysis buffer. The
samples were incubated for 2 h at 4°C, and the beads washed three
times with 1.0 ml of the N-P40 lysis buffer. MBP-paxillin-associated
protein was eluted with SDS sample buffer, resolved by 12% SDS–
PAGE, and 35S-labeled BE6 proteins detected by auto radiography. (B)
A charged leucine motif blocks interaction of BE6 and paxillin in the
absence of mammalian proteins. Expression and purification of GST
and maltose fusion proteins in BL21-lysS bacteria are as previously
described (Vande Pol et al., 1998). Twenty-five microliters of clarified
acterial lysates expressing the indicated GST fusions to BE6 and BE6
utants and MBP fusion to paxillin was mixed together in 1.0 ml of 0.5
N-P40 lysis buffer for 1 h on ice. Lane 1 contains bacterial lysate
ithout GST expression. MBP-paxillin and paxillin-associated GST fu-
ion proteins were isolated on maltose agarose beads. The beads
ere washed three times in 1.0 ml of binding buffer and retained
roteins separated by SDS–PAGE, were transferred to PVDF mem-
ranes, and GST proteins were detected with a rabbit antibody to GST
ollowed by goat anti-rabbit antibody coupled to peroxidase and chem-
iluminescent detection.ments by immune fluorescence and subcellular fraction-
ation (unpublished observations).
m
cThe inhibition of transformation by a fused CL motif
clarifies the mechanism of transformation by BE6. It is
possible that transformation by BE6 requires a strong
interaction with a charged leucine motif that structures
BE6 in a new conformation that is permissive for trans-
formation. In this hypothesis, the specific function of the
BE6-interacting cellular proteins might not be linked to
the ability of BE6 to induce anchorage-independent cell
growth. This model is unlikely because we find that BE6
molecules that can bind to an intramolecular charged
leucine motif fail to induce transformation of C127 cells,
while mutation of the inhibitory charged leucine motif
restores transformation by the fusion protein. CL pep-
tides that bound BE6 well caused an almost complete
inhibition of transformation when fused to BE6, whereas
peptides with low affinity caused partial repression of
transformation. BE6 fused to a similar peptide with no
observed binding to BE6 (CL-L4I/L8I) was similar in
transformation to wild-type BE6. Because the ability of a
fused CL peptide to repress transformation correlates
with its in vitro binding to a MBP-BE6 fusion, it is most
ikely that repression of transformation by fused peptides
s due to intramolecular binding of the CL peptide to the
E6 portion of the fusion. Such intramolecular binding
hen prevents in vivo interaction of the BE6 portion of the
usion with intracellular molecules such as paxillin. It is,
owever, still possible that the interaction of BE6 with the
used charged leucine motif is functionally dissimilar to
he interaction on multiple native target cellular proteins
r constrains BE6 into a conformation that is not permis-
ive for transformation. If the interaction of BE6 with the
used CL peptides resulted in gross distortion of BE6,
hen the reduction in transformation observed in Fig. 4
ould be due to the loss of a hypothetical function of BE6.
It is interesting that the expression level of transfor-
ation positive CL(L4I/L8I)-BE6 was lower than that of
ransformation-negative CL-BE6, but much lower than
ransformation-positive wild-type BE6. We find that trans-
ormation by BE6 mutants does not always correlate with
xpression levels. Indeed, plasmids that express BE6
rom stronger promoters (such as CMV or SV40 early
romoters) give rise to little or no transformation (unpub-
ished observations). Also, BE6 protein levels in retrovi-
ally transduced cells fall after infection when the cells
re passaged, while the anchorage-independent growth
f those cells increases. We interpret this as a selection
or low appropriate levels of BE6 expression as cells are
assaged after retroviral transduction. It is possible that
selection for appropriate expression levels of BE6 may
esult in variability of expression levels between wild-
ype BE6 and BE6 mutants.
The results of this study indicate that binding to a
harged leucine motif alone is not sufficient for transfor-
ation by BE6. The most likely interpretation is that BE6
ust interact with charged leucine motifs found on spe-
ific cellular proteins. Although several such BE6-inter-
freque
ere ob
168 BOHL ET AL.acting proteins have been proposed as targets for trans-
formation by BE6 (Chen et al., 1995; Tong et al., 1998;
FIG. 4. An intramolecular charged leucine motif blocks transformatio
in pBabe puro (Morgenstern and Land, 1990) were used to infect C12
passed three times and then assayed for transformation. (A) 105 cells
trypsinized and counted. Results are expressed as cells per cm2. (B
anchorage-independent cell growth as previously described (Ned et
frequency of colony formation. Representative pictures are shown. The
24%, in the experiment shown. No anchorage-independent colonies wTong and Howley, 1997; Vande Pol et al., 1998), there is
uncertainty about which interactions are necessary fortransformation since these proteins interact with BE6
through similar motifs. A recent mutational analysis of
E6. BE6, CL-BE6, and CL-mutant-BE6 genes packaged as retroviruses
(A) Pooled puromycin-resistant colonies (104 for each plasmid) were
eded into a 5-cm tissue culture dish. Seven days later the cells were
same cell lines assayed in (A) were seeded into agar to assay for
7). Cell colonies were photographed 2 weeks later to determine the
ncy of colony formation by wild-type BE6-transduced C127 cells was




al., 199BE6 transformation was consistent with paxillin being a


















169REPRESSION OF E6 TRANSFORMATIONThe results of this study have theoretical implications
for the treatment of papillomavirus-induced diseases. We
have shown that BE6 can interact well with charged
leucine molecules that are divergent from the conserved
binding motifs found on its cellular interacting protein
paxillin. It is thus possible that small molecules that
block interaction of BE6 with paxillin might not disrupt
the unknown cellular interactions mediated by the LD
motif on paxillin. By analogy, small molecules that block
the interaction of HPV E6 proteins with target cellular
proteins might inhibit essential viral functions in human
papillomavirus infections.
MATERIALS AND METHODS
Cells and tissue culture
Murine C127 cells were maintained in DMEM media
supplemented with 10% newborn calf serum, glutamine,
and antibiotics. Cell transformation assays for anchor-
age independent cell growth were performed as previ-
ously described (Ned et al., 1997).
Plasmids
Glutathione–S transferase (GST) and maltose binding
protein (MBP) fusions to BE6 and paxillin have been
previously described (Vande Pol et al., 1998). CL-BE6
was created by PCR with 59 oligonucleotide GAATTCAC-
ATGGACGACCTCGATGCCTTACTGGCAGACAAGGAAG-
AGGAGGAATGGACCTGAAACCTTTTG and 39 oligonu-
cleotide TCTGAATTCAGATCTCACTCGAGCTATGGG-
TABLE 1
A Charged Leucine Motif in cis Represses Transformation by BE6
Transduced Genea
Colony Formationb
Exp. 1 Exp. 2 Exp. 3
BE6 100 100 100
Vector 0 0 0
CL-BE6 2.1 4.3 0.05
CL(L8F)-BE6 4.1 4.0 N.D.c
CL(D3A)-BE6 6.4 9.3 N.D.
CL(D5A)-BE6 14 18 N.D.
CL(L4I/L8I)-BE6 44 42 92
a Wild-type BE6 or BE6 fused at the amino terminus to the CL peptide
r the indicated CL mutant peptides were retrovirally transduced (vec-
or is empty retroviral plasmid).
b More than 105 retrovirally transduced puromycin-resistant C127
olonies were pooled, were passed three times, and were assayed for
nchorage-independent growth as described in the legend to Fig. 4.
olony formation efficiency for wild-type BE6 in experiments 1–3 was
4, 28, and 20.5%, respectively. Colony formation shown is the percent-
ge observed relative to wild-type BE6 normalized to 100.
c N.D., not done.TATTTGGACCTTGAAC with wild-type BE6 as a template.
Mutations in the CL motif were created in the same
S
Wfashion by variation in the 59 oligonucleotide. The EcoRI-
and XhoI-cut products were cloned into pGEX-4T and
pBabe-puro, were sequenced, and were found without
polymerase-generated mutations. MBP and GST fusions
were expressed in Escherichia coli strain DH5 alpha and
purified onto amylose–Sepharose or glutathione–
Sepharose beads as described (Ausubel et al., 1995).
n vitro translation and in vitro binding assays
A GST fusion to paxillin was PCR amplified using a 59
oligonucleotide containing a T7 RNA polymerase binding
site and annealing to the 59 end of the GST coding
sequence and a 39 oligonucleotide annealing to the first
45 nucleotides of paxillin. This generates a PCR product
that can be in vitro transcribed by T7 RNA polymerase
and translated in reticulocyte lysate to yield GST fused to
the first 15 amino acids of paxillin. GST–paxillin proteins
with mutations in the paxillin LD binding motif were
generated in the same fashion by using 39 oligonucleo-
tides encoding specific mutations in the paxillin se-
quence, followed by in vitro transcription and translation
of the resulting PCR generated templates. In vitro cou-
pled transcriptions and translations were performed as
described (Vande Pol et al., 1998). Binding of in vitro
expressed and 35S-labeled GST–paxillin-1–15 to 1mg of a
bacterially expressed maltose binding protein (MBP) BE6
fusion immobilized on amylose–agarose beads was per-
formed for 4 h at 4°C in 0.5 3 N-P40 lysis buffer (13
N-P40 lysis buffer is 0.15 M NaCl; 0.05 M TrisCl, pH7.5; 50
mM NaF; 5 mM Na pyrophosphate; 0.5 mM sodium
vanadate; 0.5 mM DTT; 0.5 mM PMSF; 1% N-P40; 1 mg/ml
FIG. 5. Expression levels of BE6, CL-BE6, and CL(L4I/L8I)-BE6 in
transduced C127 cells. Cells (2 3 107) from the same cell lines ana-
yzed for transformation in Fig. 4 were lysed in 1% SDS lysis buffer,
riefly were sonnicated to shear DNA, and then were diluted 1:10 in
-P40 lysis buffer. One half of each sample was subjected to immune
recipitation with a rabbit polyclonal antibody to BE6 and the other half
ith a rabbit polyclonal antibody to the BPV-1 E7 oncoprotein (antibody
o BE7 was used as nonspecific rabbit control antibody, as BE7 is not
xpressed in these cell lines). Immune precipitates were resolved by
DS–PAGE, transferred to PVDF membranes and were analyzed by
estern blot with rabbit anti-BE6 antibody.
170 BOHL ET AL.aprotinin; 0.5 mg/ml leupeptin). Beads were washed
three times with 1.0 ml of binding buffer, and retained
GST–LD proteins were analyzed by SDS–PAGE and
quantitative gel scanning for 35S.
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